Two faces of the same coin non alcoholic fatty liver disease; with and without diabetes: Comparative clinico pathological analysis: A cross sectional observational study by Syed Mushfiq, Ghulam Nabi Yatoo, Bilal Ahmad Mir, Zubaida Rasool

“…Background and Aim: Non-alcohol fatty liver disease (NAFLD) is a metabolic disorder that represents the hepatic manifestation of systemic process, and is a strong risk factor for diabetes Meletus, whereas the presence of DM increases the severity of NAFLD/NASH and its progression. …”
Get full text

Factors Affecting Health-Related Quality of Life and Physical Activity after Liver Transplantation for Autoimmune and Nonautoimmune Liver Diseases: A Prospective, Single Centre Study by Katarzyna Kotarska, Ewa Wunsch, Agnieszka Kempińska-Podhorodecka, Joanna Raszeja-Wyszomirska, Dimitrios P. Bogdanos, Maciej Wójcicki, Piotr Milkiewicz

“…The autoimmune etiology of liver disease does not influence HRQoL and physical activity after LTx.…”
Get full text

Correlation between liver fibrosis in non-alcoholic fatty liver disease and insulin resistance indicators: a cross-sectional study from NHANES 2017–2020 by Bo Yang, Mingsu Gong, Xiaojie Zhu, Yang Luo, Ruiqiu Li, Hai Meng, Yuhan Wang

Subjects: “…non-alcoholic fatty liver disease…”
Get full text

A narrative review about cognitive impairment in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD): Another matter to face through a holistic approach by Marica Meroni, Miriam Longo, Erika Paolini, Paola Dongiovanni

“…Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic hepatic disorder worldwide in both adults and children. …”
Get full text

AlphaFold-based AI docking reveals AMPK/SIRT1-TFEB pathway modulation by traditional Chinese medicine in metabolic-associated fatty liver disease by Lulu Zhang, Yi Zheng, Mingyan Shao, Aiping Chen, Meiyi Liu, Wenlong Sun, Tianxing Li, Yini Fang, Yang Dong, Shipeng Zhao, Hui Luo, Juan Feng, Qi Wang, Lingru Li, Yanfei Zheng

“…Metabolic-associated fatty liver disease (MAFLD) is a chronic, progressive disorder characterized by hepatic steatosis and excessive lipid accumulation. …”
Get full text

Expression Analysis of ATP-Binding Cassette Transporters ABCB11 and ABCB4 in Primary Sclerosing Cholangitis and Variety of Pediatric and Adult Cholestatic and Noncholestatic Liver Diseases by Cornelia Thoeni, Ruediger Waldherr, Jutta Scheuerer, Stefanie Schmitteckert, Ralph Roeth, Beate Niesler, Ernest Cutz, Christa Flechtenmacher, Benjamin Goeppert, Peter Schirmacher, Felix Lasitschka

“…Therefore, ABCB11 and ABCB4 expressions were investigated on formalin-fixed and paraffin-embedded (FFPE) material in a patient cohort of total 43 patients with or without cholestatic liver diseases, on protein level using immunohistochemistry and on RNA level using nanoString technology. …”
Get full text

PLEYOTROPIC EFFECTS OF METFORMIN by L. Ju. Morgunov

Subjects: “…nonalcoholic fatty liver disease…”
Get full text

The immunoregulatory effects of scoparone on immune-mediated inflammatory diseases by Feifei Qiu, Jingru Lin, Xiaofei Huang, Bin Yang, Weihui Lu, Weihui Lu, Zhenhua Dai, Zhenhua Dai

Subjects: Get full text

Higher intakes of lysine, threonine and valine are inversely associated with non-alcoholic fatty liver disease risk: A community-based case-control study in the Chinese elderly by Xueqi Li, Wenjun Ma, Ting Yang, Chong Wang, Wei Zhang, Hui Li, Ting Zhao, Xiaofei Guo

Subjects: “…Non-alcoholic fatty liver disease…”
Get full text

Comparative Evaluation of Whole Body and Hepatic Insulin Resistance Using Indices from Oral Glucose Tolerance Test in Morbidly Obese Subjects with Nonalcoholic Fatty Liver Disease by Kamran Qureshi, Ronald H. Clements, Fahad Saeed, Gary A. Abrams

“…Nonalcoholic Fatty Liver Disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is a marker of Insulin Resistance (IR). …”
Get full text

Iodine-131 Combined With Plasma Exchange Treatment in Graves’ Hyperthyroidism Patients With Severe Liver Injury Whose Average Model for End-Stage Liver Disease Scores >20 by Xin-Fang Zhu, Rong-Rong Ding, Bing-Yao Wang, Yun-hui Yang, Fu-Xia Ta, Yuan Wang, Qing-Mei Gao, Qi Zhang, Rong Xia, Xing-Guang Luo, Xuan Wang, Jian-Ming Zheng, Hui-Qing Zhu

“…Results: In this study, there were 8 patients included, the average model for end-stage liver disease (MELD) scores were greater than 20 (ranges from 19 to 30) at baseline. …”
Get full text

Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease by Xinyue Li, Xiaojuan Wu, Yumei Jia, Jing Fu, Lin Zhang, Tao Jiang, Jia Liu, Guang Wang

“…In this study, we aimed to verify plasma fibroblast growth factor 21 (FGF21) elevation in newly diagnosed overweight patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) and to evaluate the effectiveness of liraglutide on reducing liver fat content and serum (FGF21) levels in those patients. …”
Get full text

Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway by Jiaxin Zhang, Haixia Du, Menglan Shen, Zhengqi Zhao, Xinmiao Ye

“…Kangtaizhi granule (KTZG) is a Chinese medicine compound prescription and has been proven to be effective in nonalcoholic fatty liver disease (NAFLD) treatment clinically. However, the underlying mechanisms under this efficacy are rather elusive. …”
Get full text

Chemogenomic Screening in a Patient‐Derived 3D Fatty Liver Disease Model Reveals the CHRM1‐TRPM8 Axis as a Novel Module for Targeted Intervention by Sonia Youhanna, Aurino M. Kemas, Shane C. Wright, Yi Zhong, Britta Klumpp, Kathrin Klein, Aikaterini Motso, Maurice Michel, Nicole Ziegler, Mingmei Shang, Pierre Sabatier, Aimo Kannt, Hongda Sheng, Nuria Oliva‐Vilarnau, Florian A. Büttner, Brinton Seashore‐Ludlow, Jonas Schreiner, Maike Windbergs, Martin Cornillet, Niklas K. Björkström, Andreas J. Hülsmeier, Thorsten Hornemann, Jesper V. Olsen, Yi Wang, Roberto Gramignoli, Michael Sundström, Volker M. Lauschke

“…Abstract Metabolic dysfunction‐associated steatohepatitis (MASH) is a leading cause of chronic liver disease with few therapeutic options. To narrow the translational gap in the development of pharmacological MASH treatments, a 3D liver model from primary human hepatocytes and non‐parenchymal cells derived from patients with histologically confirmed MASH was established. …”
Get full text

Effects of celastrol on the heart and liver galaninergic system expression in a mouse model of Western-type diet-induced obesity and metabolic dysfunction-associated steatotic liver disease and steatohepatitis by Nikolina Canová, Jana Šípková, Mahak Arora, Zuzana Pavlíková, Zuzana Pavlíková, Tomáš Kučera, Ondřej Šeda, Tijana Šopin, Tomáš Vacík, Ondřej Slanař

“…Therefore, this study aimed to investigate the effects of celastrol on the galaninergic system expression in the heart and liver of mice suffering from diet-induced obesity and metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH).MethodsThe male mice C57BL/6J were fed a Western-type high-fat diet for 16 and 20 weeks to induce obesity and MASLD/MASH. …”
Get full text

The Effects of Extra Virgin Olive Oil on Alanine Aminotransferase, Aspartate Aminotransferase, and Ultrasonographic Indices of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Patients Undergoing Low Calorie Diet by Farzad Shidfar, Samaneh Sadat Bahrololumi, Saeid Doaei, Assieh Mohammadzadeh, Maryam Gholamalizadeh, Ali Mohammadimanesh

“…Coronary artery disease is the most common cause of death in the patients with nonalcoholic fatty liver disease (NAFLD). Studies have shown that there is a strong relation between the increase in the aminotransferase levels and fat accumulation in the liver with cardiovascular complications, independent of all aspects of the metabolic syndrome. …”
Get full text

A randomized double-blind clinical trial investigating the effects of ellagic acid on glycemic status, liver enzymes, and oxidative stress in patients with non-alcoholic fatty liver disease by Sara Mighani, Rasoul Samimi, Mohamadreza Rashidi Nooshabadi, Seyed Amir Farzam, Hossein Khadem Haghighian, Maryam Javadi

Subjects: “…Non-alcoholic fatty liver disease…”
Get full text

Clostridium Scindens Protects Against Vancomycin‐Induced Cholestasis and Liver Fibrosis by Activating Intestinal FXR‐FGF15/19 Signaling by Jintao Xiao, Yanliang Hou, Xingyang Luo, Yuhao Zhu, Wenhu Li, Bingbing Li, LinXiang Zhou, Xia Chen, Ying Guo, Xiaomei Zhang, Haiyue He, Xiaowei Liu

Subjects: “…cholestatic liver diseases…”
Get full text

Non-invasive methods for diagnosing portal hypertension and variceal bleeding due to liver cirrhosis secondary to NAFLD/MASLD: systematic review by Nebyu Yonas Shanka, Nebyu Yonas Shanka, Chavdar S. Pavlov, Nigatu Leul Mekonnen

Subjects: “…non-alcoholic fatty liver disease…”
Get full text

Nutritional assessment using subjective global assessment identifies energy malnutrition and predicts mortality in patients with liver cirrhosis by Takao Miwa, Tatsunori Hanai, Kayoko Nishimura, Sachiyo Hirata, Shinji Unome, Yuki Nakahata, Kenji Imai, Atsushi Suetsugu, Koji Takai, Masahito Shimizu

Subjects: “…Chronic liver disease…”
Get full text